Currently, DYN101, an AO therapeutic designed by Dynacure to modulate the expression of DNM2 entered an early-phase trial clinical trial (NCT04033159) on centronuclear myopathy patients. This evidence concerns the gene DNM2 and autosomal dominant centronuclear myopathy.